ARS Pharmaceuticals, Inc.
SPRYNASDAQHealthcare● Active
$8.99
+$0.43(+5.02%)
Market Cap$892736325
P/E Ratio—
52W High$18.9
52W Low$6.66
ARS Pharmaceuticals, Inc. (SPRY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SPRY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $84.28M | $89.15M | $0.03M | $1.32M | $5.51M |
| Cost of Revenue | $20.42M | $20.56M | $0.00M | $17.12M | $0.21M |
| Gross Profit | $63.85M | $68.59M | $0.03M | ($15.80M) | $5.29M |
| Gross Margin %(computed) | 75.77% | 76.94% | 100.00% | — | 96.13% |
| Operating Expenses | |||||
| R&D Expenses | $13.18M | $19.58M | $20.27M | $18.38M | $20.27M |
| G&A Expenses | $0.00M | $0.00M | $47.28M | $18.46M | $4.69M |
| Total Operating Expenses | $243.30M | $71.67M | $67.55M | $19.71M | $24.75M |
| Operating Income | ($179.45M) | ($3.08M) | ($67.52M) | ($35.52M) | ($19.45M) |
| Operating Margin %(computed) | -212.92% | -3.46% | — | — | -353.32% |
| Interest Income | $10.67M | $0.00M | $0.00M | $0.00M | $0.80M |
| Interest Expense | $2.60M | $0.00M | $0.00M | $0.00M | $0.11M |
| Income Before Tax | ($171.38M) | $8.29M | ($54.37M) | ($34.68M) | ($20.24M) |
| Income Tax Expense | ($0.08M) | $0.29M | $0.00M | $0.00M | $0.00M |
| Net Income | ($171.30M) | $8.00M | ($54.37M) | ($34.68M) | ($20.24M) |
| Net Margin %(computed) | -203.25% | 8.97% | — | — | -367.65% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 |
| Wtd Avg Shares | 98.57M | 96.94M | 95.22M | 39.96M | 28.87M |
| EBITDA | ($178.08M) | ($3.00M) | ($67.45M) | ($35.20M) | ($19.24M) |
| EBITDA Margin %(computed) | -211.30% | -3.37% | — | — | -349.46% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more ARS Pharmaceuticals, Inc. data
About ARS Pharmaceuticals, Inc. (SPRY) Income Statement
ARS Pharmaceuticals, Inc. (SPRY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SPRY reported revenue of $0.08B, gross profit of $0.06B (gross margin 75.77%), and net income of ($0.17B) — a net profit margin of -203.25%.
Frequently asked questions
SPRY · 4 questionsARS Pharmaceuticals, Inc. (SPRY) reported revenue of $0.08B for 2025, down 5.5% year-over-year.
SPRY revenueSPRY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09